%20(1).webp)
Best Peptides for Energy and Performance: What the Research Actually Shows
Updated: Sep 7
If the problem is low cellular output, MOTS-c makes more sense than a repair peptide. If pain or a stubborn tendon is limiting training, BPC-157 may be the better fit. If inflammation and stiffness are the main problem, KPV belongs near the top of the list. When appetite, body weight, or glucose control is driving fatigue, retatrutide is a different—and more relevant—tool.
This guide explains practical benefits, combinations, study protocols, and firsthand observations documented by Kelden Peptides Canada in simple language. It also connects readers with Kelden's broader peptide research library and links directly to the published literature behind each section.
Best options by goal
Fastest perceived energy in Kelden's documented observations: MOTS-c, NAD+, and SLU-PP-332
Cellular energy and endurance: MOTS-c
One painful joint, tendon, or injury area: BPC-157
Inflammation, swelling, and stiffness: KPV
Broader soreness, flexibility, and soft-tissue recovery: TB-500
Body weight, appetite, and glucose control: Retatrutide
Skin, hair, wound, and connective-tissue support: GHK-Cu
Slower metabolic support: 5-Amino-1MQ
Focused mitochondrial research: SS-31 / elamipretide
No single option does all of these jobs. The most useful approach is to choose one main target, then combine only when a second compound has a different role.
Benefits at a glance
MOTS-c
Noticeable energy and willingness to move
Metabolic flexibility—the ability to switch between available fuel sources
AMPK signalling, which helps cells respond when energy demand rises
Glucose uptake and insulin-sensitivity research
Exercise adaptation, endurance, and age-related physical-capacity research
BPC-157
Localized joint and tendon support
Less soreness around a problem area
Easier movement when pain is the limiting factor
Tendon-fibroblast movement and repair-signalling research
Growth-hormone-receptor expression in tendon-cell models
KPV
Less perceived inflammation and swelling
Better flexibility
A calmer overall feeling in Kelden's documented observations
PepT1 intestinal-uptake research
Gut-barrier and inflammatory-signalling research
TB-500
Broader soft-tissue recovery
Less generalized soreness
Better flexibility and movement
Cell migration, actin dynamics, and tissue-remodelling research
Useful when the issue is not limited to one small area
Retatrutide
Strong appetite reduction
Major body-weight reduction in human trials
Better glucose control
Improvements in waist circumference and insulin-resistance markers in trials
Indirect improvement in mobility and day-to-day output when metabolic health is the bottleneck
GHK-Cu
Tissue remodelling and wound support
Collagen and extracellular-matrix research
Skin-quality and hair-follicle research
Connective-tissue and wound-closure research
A useful support compound rather than a direct energy compound
Combination frameworks
These combinations are easy to understand because every compound has a separate job.
Simple foundation: MOTS-c + KPV + GHK-Cu
This is the broad beginner framework used most often in Kelden's documented observations.
MOTS-c: energy and mitochondrial support
KPV: inflammation, swelling, and flexibility
GHK-Cu: tissue, skin, hair, and connective-tissue support
It covers three different targets without using several compounds for the same purpose.
Energy plus localized recovery: MOTS-c + BPC-157 + KPV
This has been one of the most useful combinations in Kelden's documented firsthand observations.
MOTS-c is the energy anchor.
BPC-157 is for the dominant joint, tendon, or injury area.
KPV supports the inflammation and stiffness side.
This combination makes more sense than expecting MOTS-c to solve an injury or expecting BPC-157 to act like an energy compound.
Whole-body recovery: MOTS-c + KPV + TB-500
This framework fits widespread soreness, stiffness, or slow recovery.
MOTS-c supports output and activity.
KPV addresses inflammation and swelling.
TB-500 adds the broader soft-tissue and flexibility angle.
Kelden's framework places BPC-157 first when one area is the clear problem and TB-500 first when the recovery issue is more general.
Metabolic fatigue: retatrutide as the anchor
Retatrutide fits when excess weight, appetite, insulin resistance, or poor glucose control is the main reason energy and movement are low.
MOTS-c can be paired with it when mitochondrial output is a separate research target. KPV may fit when inflammation is also limiting movement. Retatrutide is not an immediate energy product; the benefits in published trials developed over months through metabolic change.
Dosage and protocols used in published research
The numbers below are the actual protocols used in published studies. This is more useful than presenting unsourced internet doses as fact. The model and route matter: a mouse injection, a topical human gel, and a controlled human trial are not interchangeable.
MOTS-c protocol
A 2022 mouse endurance study used a single 15 mg/kg dose in untrained mice. Running time increased by 12%, and running distance increased by 15%.
That study gives a clear endurance signal in mice. It does not establish a human dose.
SS-31 / elamipretide protocol
The MMPOWER-3 trial used 40 mg subcutaneously once daily for 24 weeks in 218 adults with primary mitochondrial myopathy.
The treatment was generally well tolerated, but it did not improve six-minute walk distance or fatigue compared with placebo in that trial.
SLU-PP-332 protocol
The main mouse study used 50 mg/kg intraperitoneally one hour before an endurance test. Other experiments used 50 mg/kg twice daily for 10 to 15 days.
The mice developed more oxidative muscle fibres and better running endurance. SLU-PP-332 is a small molecule, not a peptide, and a human protocol has not been established.
NAD+ protocol
A human pilot study infused 750 mg intravenously over six hours and measured NAD+ metabolites in plasma and urine.
The study showed how intravenous NAD+ was processed. It was not designed as a performance trial.
5-Amino-1MQ protocol
The original obesity research used repeated injections in mice totalling about 34 mg/kg per day.
The model showed lower fat mass and metabolic changes. Human efficacy and dosing were not tested.
BPC-157 protocol
A two-person human safety pilot infused 10 mg on day one and 20 mg on day two, with each dose given over one hour.
Both participants completed the protocol without reported adverse effects. The study tested short-term safety measurements, not injury healing or athletic performance.
KPV protocol
Published KPV studies have mainly used intestinal cell systems and mouse colitis models. There is no established injected human KPV protocol in the published literature.
TB-500 / thymosin beta-4 protocol
Human wound research has studied topical full-length thymosin beta-4. That is not the same as an injectable protocol for the shorter TB-500 fragment sold in the research market.
GHK-Cu protocol
A multicentre human diabetic-ulcer trial used a metered topical copper-tripeptide gel once daily as part of standardized wound care. The copper-tripeptide group had faster wound closure than the vehicle group.
Retatrutide protocol
The phase 2 obesity trial tested 1, 4, 8, and 12 mg subcutaneously once weekly for 48 weeks. Higher-dose groups used dose escalation, and gastrointestinal events were lower when escalation began at 2 mg rather than 4 mg.
For laboratory concentration and draw-volume calculations after a protocol has been selected, use the Kelden Peptides Canada dosage calculator. Product-specific testing can be reviewed through third-party lab reports and available microbiology reports.
MOTS-c: a leading option for direct energy
MOTS-c is produced from mitochondrial DNA. In simple terms, it signals cells to respond when energy demand rises.
Main benefits
Better perceived daily energy
Greater willingness to move or exercise
Easier stair climbing and physical activity in Kelden's observations
Better metabolic flexibility under changing energy demand
AMPK activation and improved glucose uptake in preclinical research
Exercise adaptation and age-related physical-capacity research
Repeated firsthand observations
MOTS-c produced one of the clearest same-day energy changes in Kelden's documented observations. At times, the perceived effect continued beyond the day of use.
The same observations included easier movement, faster stair climbing, and more willingness to be physically active. The effect appeared more obvious when low cellular energy was the main limitation and less obvious when pain, inflammation, poor sleep, or another issue remained unresolved.
Best combinations
KPV: when stiffness or inflammation reduces the benefit of having more energy
BPC-157: when one joint or tendon is limiting activity
GHK-Cu: for a broad energy-plus-tissue foundation
Retatrutide: when mitochondrial and metabolic goals are separate
The original Cell Metabolism study connected MOTS-c with AMPK activity and metabolic control in mice. A later human exercise study found that the body's own MOTS-c increased with exercise. A 2022 mouse study reported better running time and distance after administered MOTS-c.
Kelden research material: MOTS-c 10 mg.
BPC-157: when pain is limiting performance
BPC-157 is not primarily an energy compound. Its practical value is that less soreness and easier movement may allow more activity and better recovery.
Main benefits
Joint and tendon comfort
Localized soft-tissue support
Less soreness around a problem area
Better mobility when pain is limiting training
Tendon-cell migration through FAK-paxillin repair signalling in laboratory research
Increased growth-hormone-receptor expression in tendon fibroblasts in laboratory research
Repeated firsthand observations
Kelden's documented observations include less soreness near the targeted area and less shoulder pain. On some occasions, the perceived change occurred within minutes and lasted for hours.
Repeated use also coincided with the problem settling over time. Clients have reported better joint comfort, flexibility, performance, and recovery. Those reports are real-world observations, not controlled trial results.
Best combinations
KPV: localized recovery plus broader inflammation support
TB-500: one dominant injury area plus whole-body soft-tissue support
MOTS-c: recovery support while keeping energy and activity central
In rat tendon-cell research, BPC-157 increased cell migration and activated FAK-paxillin signalling involved in repair. Another tendon-cell study found increased growth-hormone receptor expression. Human observations include a small knee-pain report and a two-person intravenous safety pilot.
Kelden research material: BPC-157 10 mg.
KPV: a standout option for inflammation and flexibility
KPV is a three-amino-acid fragment of alpha-MSH. Its main role in this framework is inflammation support.
Main benefits
Less perceived inflammation and swelling
Better flexibility and easier movement
A calmer overall feeling in Kelden's documented observations
Uptake through the intestinal PepT1 transporter in laboratory research
Lower inflammatory signalling in intestinal cell and mouse-colitis models
Gut-focused research without overlapping the direct energy role of MOTS-c
Easy to combine because it has a different role from energy and repair compounds
Repeated firsthand observations
KPV has been a standout compound in Kelden's documented observations, repeatedly associated with less swelling, less perceived inflammation, better flexibility, and a calmer feeling.
It has also been one of the most useful support compounds in a combination because inflammation can limit the benefit of an energy or recovery protocol.
Best combinations
MOTS-c: energy plus inflammation support
BPC-157: inflammation plus localized recovery
TB-500: inflammation plus broader soft-tissue support
GHK-Cu: a simple foundation with tissue support
Published cell and mouse research found that KPV entered intestinal cells through the PepT1 transporter and reduced inflammatory signalling. A separate mouse colitis study also reported lower inflammatory activity.
Kelden research material: KPV 10 mg.
TB-500: broader recovery and flexibility
TB-500 is generally placed in a whole-body soft-tissue and flexibility framework. Its role is broader than the localized role Kelden assigns to BPC-157.
Main benefits
Better whole-body recovery
Less generalized soreness
Better flexibility and movement
Cell migration and actin-dynamics research relevance
Blood-vessel formation and wound-closure research involving full-length thymosin beta-4
Muscle-regeneration and soft-tissue-remodelling research involving full-length thymosin beta-4
Repeated firsthand observations
Kelden's documented observations associate TB-500 with less generalized body pain, better flexibility, and easier recovery. Kelden places it ahead of BPC-157 when soreness is widespread rather than centred on one joint or tendon.
Best combinations
BPC-157: localized plus broader recovery
KPV: recovery plus inflammation support
MOTS-c: energy plus recovery when physical load is high
Product identity matters. A mass-spectrometry study identified the shorter TB-500 fragment after equine administration. Much of the repair literature used full-length thymosin beta-4, including muscle-regeneration research and wound research.
Kelden research material: TB-500 10 mg.
Retatrutide: strongest human results for metabolic change
Retatrutide activates GIP, GLP-1, and glucagon receptors. It belongs in this guide when poor metabolic health is the reason energy and movement are low.
Main benefits shown in human trials
Major body-weight reduction
Appetite reduction
Better glucose control
Better insulin-resistance markers
Reduced waist circumference and broader metabolic-marker changes
Easier movement over time as body weight decreases
In the phase 2 obesity trial, average weight loss at 48 weeks reached 24.2% in the 12 mg group, 22.8% in the 8 mg group, and 17.1% in the combined 4 mg groups. A separate type 2 diabetes trial reported dose-dependent improvements in glucose control and body weight.
Where it fits
Retatrutide is the most relevant anchor when appetite, body weight, insulin resistance, or glucose control is the main bottleneck. It is not the first choice when the real limitation is a shoulder, tendon, systemic inflammation, or low mitochondrial output.
Combination logic
MOTS-c: metabolic change plus a separate mitochondrial-energy target
KPV: metabolic support plus an inflammation target
BPC-157: only when a separate injury is limiting activity
The most common trial issues were gastrointestinal, including nausea, vomiting, and diarrhea. The trials also recorded a temporary dose-dependent increase in heart rate.
Kelden research material: Retatrutide 20 mg.
Other options worth knowing
NAD+
NAD+ is a coenzyme, not a peptide. It is central to redox reactions and cellular energy.
Its distinct research interests include redox recycling, ATP-production support, and its role as a cofactor for sirtuins and PARPs involved in cellular stress responses.
Kelden's documented observations include a same-day energy increase with NAD+, sometimes lasting beyond the day of use. Its perceived timing was closer to MOTS-c, although the pathways are different.
The human intravenous pilot used 750 mg over six hours and measured changes in circulating and urinary metabolites.
Kelden research material: NAD+ 500 mg.
5-Amino-1MQ
5-Amino-1MQ is an NNMT inhibitor, not a peptide. The main interest is fat metabolism and energy balance.
Its unique research angle is NNMT inhibition in adipose tissue, with interest in fat-mass regulation, cellular methylation demand, and energy balance.
The response in Kelden's documented observations was slower than with MOTS-c or NAD+, becoming noticeable at roughly one week rather than on the first day.
The original mouse study reported lower fat mass and metabolic changes in diet-induced obesity.
Kelden research material: 5-Amino-1MQ 50 mg.
SLU-PP-332
SLU-PP-332 is an ERR agonist and technically a small molecule, not a peptide.
Its research interest includes oxidative muscle-fibre development, fatty-acid oxidation, mitochondrial capacity, and activation of an aerobic-exercise gene program.
Kelden's documented observations include a rapid change in perceived energy and mobility, along with more running. It produced one of the most immediate perceived effects among the compounds reviewed here.
In the primary mouse study, it activated an aerobic-exercise gene program, increased oxidative type IIa muscle fibres, and improved running endurance.
SS-31 / elamipretide
SS-31 is designed to concentrate around the inner mitochondrial membrane and bind cardiolipin. It is studied for cristae structure, electron transport, oxidative phosphorylation, oxidative stress, and cellular energy efficiency.
The MMPOWER-3 human trial is useful because it shows both sides of the evidence: the mitochondrial mechanism is strong, but 40 mg daily did not improve walking distance or fatigue in that specific disease population.
Kelden research material: SS-31 10 mg.
GHK-Cu
GHK-Cu is a copper-binding tripeptide. Its best fit is tissue remodelling, collagen and extracellular-matrix research, wound closure, skin quality, and hair-follicle support—not a direct energy boost.
A multicentre diabetic-ulcer trial reported faster wound closure with a daily topical copper-tripeptide gel than with vehicle.
Kelden research material: GHK-Cu 50 mg.
A practical way to track a protocol
The clearest results come from changing fewer variables.
Choose one main outcome: daily energy, endurance, pain, swelling, flexibility, body weight, or recovery time.
Record a seven-day baseline.
Choose one anchor compound that matches the main problem.
Add only one companion when it covers a separate target.
Keep the same weekly measures: energy from 1–10, steps or training volume, pain from 1–10, swelling, sleep, and next-day recovery.
Review the trend instead of judging the protocol from one unusually good or bad day.
Benefits repeated most often in firsthand observations
Fastest perceived energy: MOTS-c, NAD+, and SLU-PP-332
Slower metabolic response: 5-Amino-1MQ, noticeable in Kelden's observations at about one week
Best localized recovery response: BPC-157
Best inflammation and flexibility response: KPV
Best broader body-comfort response: TB-500
Best controlled human results for weight and glucose: retatrutide
Best simple foundation: MOTS-c + KPV + GHK-Cu
Most useful energy-and-recovery combination in Kelden's documented observations: MOTS-c + BPC-157 + KPV
The main lesson is simple: energy, inflammation, injury, and metabolic health are different problems. The best peptides for energy and performance are easier to compare when every compound has one clear job.
Kelden Peptides Canada research resources
Review available third-party lab reports.
Review available microbiology reports.
Use the dosage calculator for concentration and draw-volume calculations.
See the Kelden Peptides Canada FAQ for storage, handling, and research-use information.
Continue reading
References
Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015.
Reynolds JC, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications. 2021.
Hyatt JPK, et al. MOTS-c increases in skeletal muscle following long-term physical activity and improves acute exercise performance in mice. 2022.
Karaa A, et al. Efficacy and safety of elamipretide in individuals with primary mitochondrial myopathy: MMPOWER-3. Neurology. 2023.
Billon C, et al. Synthetic ERR agonist induces an acute aerobic exercise response and enhances exercise capacity. ACS Chemical Biology. 2023.
Grant R, et al. Human plasma and urine NAD+ metabolome during a six-hour intravenous NAD+ infusion. Frontiers in Aging Neuroscience. 2019.
Neelakantan H, et al. Selective NNMT inhibitors reverse high-fat-diet-induced obesity in mice. Biochemical Pharmacology. 2018.
Chang CH, et al. BPC-157 and tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology. 2011.
Chang CH, et al. BPC-157 enhances growth-hormone receptor expression in tendon fibroblasts. Molecules. 2014.
Lee E, Burgess K. Safety of intravenous infusion of BPC-157 in humans: a pilot study. 2025.
Dalmasso G, et al. PepT1-mediated KPV uptake reduces intestinal inflammation. Gastroenterology. 2008.
Kannengiesser K, et al. KPV has anti-inflammatory potential in murine colitis. Inflammatory Bowel Diseases. 2008.
Ho ENM, et al. Identification of TB-500 in equine plasma and urine by mass spectrometry. 2012.
Mulder GD, et al. Enhanced healing of diabetic ulcers with topical GHK-Cu. Wound Repair and Regeneration. 2007.
Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. New England Journal of Medicine. 2023.
Rosenstock J, et al. Retatrutide in adults with type 2 diabetes: a phase 2 trial. The Lancet. 2023.
Research-use disclaimer: This article summarizes published literature and firsthand observations for educational purposes. Kelden Peptides Canada products are supplied strictly for laboratory research use and are not approved for human consumption, diagnosis, treatment, or prevention of disease.
